After promising results from Reata's Phase 2a study of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes, the Phase 2b study will look to confirm previous findings in a larger population with more severe kidney damage. This study is looking at the effects of bardoxolone methyl in patients with type 2 diabeties mellitus and chronic kidney disease on eGFR and other perameters of kidney function. Patients were randomized to one of three doses of bardoxolone methyl or placebo and are being followed for one year.

 

 

This Phase 2 study is testing a new formulation of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.  Patients will receive one of several doses of bardoxolone methyl for 12 weeks.